We report two potent DNAzymes, DNZ-15 and DNZ-35a, which downregulate BCL-2 expression in cancer cell lines and suppress tumor growth in a murine cancer model, thus providing a foundation for future DNAzyme-based cancer therapeutics. The gene discussed is BCL2; the disease is cancer.